Newsroom Archives - Page 2 of 23 - Spectral Medical Inc

Spectral Medical and Vantive Announce Publication of Complete Results from Spectral’s Tigris Trial in the Lancet Respiratory Medicine

Tigris publication confirms positive results for primary and key secondary endpoints with 95.3% and 99.4% probability of benefit for PMX at 28-day and 90-day mortality After adjusting for baseline severity, absolute risk reduction for mortality of 10.3% at 28-days...

Spectral Medical Provides Update on PMA Submission Timing for PMX-20R

TORONTO, Canada – February 26, 2026 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the timing of its Premarket Approval...

Spectral Medical Announces Third Quarter 2025 Financial Results and Provides Corporate Update

PMA submission targeted for Q1 2026 following positive Tigris results and ongoing FDA interactions Company to host Corporate Update call on Wednesday, December 10, 2025 TORONTO, Canada – Nov. 07, 2025 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX:...

Spectral Medical Inc. Files Base Shelf Prospectus and Revised AIF

TORONTO, Canada – September 29, 2025 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, announced that it has filed a final short form base shelf...

Spectral Medical Announces Publication of EDEN Observational Study

New Study Strengthens Rationale for Spectral’s PMX Therapy by Defining Endotoxic Septic Shock (ESS) as the Highest-Risk Patient Group TORONTO, Canada – September 16, 2025 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic...

Spectral Medical Sponsors Unite for Sepsis Symposium, Chicago September 8 – 9, 2025

Company to present at session titled “Personalizing Sepsis Treatment” TORONTO, Canada – September 8, 2025 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic...

« Older Entries

Next Entries »

EAA™ and PMX are licensed and available for use in Canada. PMX is not approved for clinical use in the USA, and is currently undergoing the PMA (Premarket approval) process. EAA™ is FDA cleared for use in the USA. The information presented herein is region specific. Please contact Spectral Medical Inc.to obtain appropriate product information for your country.